Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.61 |
| ▸ | ACE | P12821 | 9/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 9/20 | 0.61 |
| ▸ | CPA1 | P15085 | 8/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.55 |
| ▸ | ITGAV | P06756 | 3/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15201783 | 1.00 | MME (0.61) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL7758997 | 0.93 | ITGB3 (0.58) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL2185240 | 0.93 | ITGB3 (0.58) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL844471 | 0.93 | ITGB3 (0.58) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL8932501 | 0.91 | HDAC1 (0.59) | MMEACEACE2CPA1 | |
| SCHEMBL2358936 | 0.90 | MME (0.51) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL3927408 | 0.90 | ACE (0.60) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL16124609 | 0.90 | ITGB3 (0.57) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL2356597 | 0.89 | CYP3A4 (0.51) | MMEACEACE2CPA1ITGB3 | |
| SCHEMBL11123913 | 0.89 | CTSL (0.54) | MMEACEACE2CPA1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964616-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2882716-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2855464-A1 | NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2814490-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014138053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| EP-2773335-A1 | NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013181332-A1 | NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| EP-2651896-A1 | NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2013123165-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID [1,3]DIOXOL-4-YLMETHYL ESTER | THERAVANCE, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123148-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012082853-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |